Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Abstract

UNLABELLED Inhibition of PARP is a promising therapeutic strategy for homologous recombination-deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-glycoprotein drug efflux transporter. Here, we… (More)
DOI: 10.1158/2159-8290.CD-12-0049

7 Figures and Tables

Topics

  • Presentations referencing similar topics